Dr. Reddy's Laboratories Ltd.

Home
Dr. Reddy's Laboratories Ltd.

We are a global pharmaceutical company committed to providing affordable & innovative medicines. Dr. Reddy’s Laboratories Ltd.

(BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first
Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Dr. Reddy’s does not collect nor does it require you to share any personal data or personal information, towards your access to or participation in the Facebook event organised by it. You are advised to not disclose any personally identifiable or confidential or non-public information on social media; you are personally responsible for any data that you may decide to share or post on any social media including on this page and Dr. Reddy’s owes no duty or obligation or liability to you or to any other person for the same. All participants on this Facebook event are required to behave with courtesy to others and to not post any offensive/objectionable messages or to intrude into any other person’s rights of privacy.

31/12/2025

As we look back at 2025, we see a year filled with celebrating excellence, people, science, innovation, and a commitment to patients and customers across the globe.

We wrap up the year with a deep sense of gratitude and a clear focus for the year ahead.

Many of you played a critical role in our journey as partners, shareholders, customers and well-wishers. We thank you for your trust and support.

We wish all of you a Happy New Year filled with good health and prosperity.

22/12/2025

Honoured to share that our Chairman, Satish Reddy, was part of the official business delegation to Oman led by Hon’ble Prime Minister Shri Narendra Modi.

He participated in the India–Oman Business Forum alongside Indian and Omani CEOs, focusing on strengthening collaboration in healthcare and pharmaceuticals.

The visit also witnessed the signing of the India–Oman Comprehensive Economic Partnership Agreement (CEPA) in the presence of the Prime Minister—a significant step toward deepening bilateral ties and advancing shared priorities in critical sectors.

17/12/2025

We had the privilege of hosting an inspiring group of global health leaders at our “The World of HIV: Invisible Battles, Visible Hope” symposium at the Leadership Academy in Bachupally, Hyderabad.

Throughout the day, we heard from experts at Clinton Health Access Initiative (CHAI):
Dr. David Ripin, Vice President, Infectious Diseases
Carolyn Amole, Vice President for HIV, Hepatitis & TB
Marie Chantale J. Lepine, President of Global Markets
Aman Siwach, Senior Director

They shared powerful insights on the current HIV/AIDS landscape and aligned on our shared mission: to reduce AIDS‑related deaths by making HIV treatment accessible, affordable, and sustainable for millions worldwide.

Joining us virtually was Elizabeth Cerqueira Murray, MBA, Executive Director– Global Patient Solutions & Voluntary License at Gilead Sciences. She highlighted how voluntary licensing of Lenacapavir can dramatically improve treatment access worldwide.

From our side, Deepak Sapra, CEO – API & Services, and Karun Gaur, Global Head – Strategic Projects – APIs, reaffirmed our commitment to tackling unmet healthcare needs and making high‑quality treatments accessible. Dr. Anil Jain, Head of Global Medical Affairs, demystified AIDS—addressing common myths, explaining disease progression, and sharing key steps toward defeating HIV.

The energy in the space was palpable—people left inspired, informed, and ready to act.

Clinton Health Access Initiative, Inc.
Gilead Sciences

12/12/2025

Building on the near-term Science Based Targets initiative (SBTi) targets announced in October 2020, we have revised our goals to Net Zero under the latest SBTi Framework. These include both near- and long-term targets.

We are proud to be the only Indian pharmaceutical company to commit to a science-based Net Zero target by FY2045. Through this commitment, we strive to strengthen our sustainability efforts and ensure responsible care of the planet.

Near-term goal: Reduce absolute Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 80%, and Scope 3 emissions by 51.6% by FY2030.

Long-term goal: Reduce emissions across all scopes by 90% by FY2045.

To read more, click: https://lnkd.in/dtcQuwdh

(Affordable and clean energy)

08/12/2025

We’ve entered into an exclusive licensing agreement for the development and commercialization of Eftilagimod Alfa (Efti) in countries outside North America, Europe, Japan, and Greater China.
Efti is Immutep’s first-in-class immunotherapy that directly activates the immune system to fight cancer. It’s currently in a registrational Phase III trial (TACTI-004 / KEYNOTE-F91) for first-line treatment of advanced or metastatic non-small cell lung cancer. The drug is also being studied for other cancers, including head & neck, breast, and soft tissue sarcoma.

Oncology remains a key focus area for us. We are building an end-to-end ecosystem of care—from providing access to standard cancer treatments globally to innovating formulations, forging strategic collaborations for novel molecules, and offering beyond-the-pill support like nutrition and digital tools.

This collaboration is another step toward our goal of reaching 1.5 billion patients by 2030 and being the partner of choice for patients and stakeholders worldwide.

Click to read more, click link in bio.

(good health and well-being)

03/12/2025

Everyone’s journey with disability is unique. At Dr. Reddy’s, we are committed to fostering inclusion and creating opportunities for persons with disabilities (PwD). Our Diversity, Equity and Inclusion (DEI) journey is young, and we have a long way to go. With each step, we try to learn and improve our effort to fairly represent the society we live in.

Through our GROW PwD initiative, in collaboration with Dr. Reddy’s Foundation, we empower youth (18–35 years) from low-income households with disabilities to join the workforce. The program offers two months of core employability training, covering communication, aptitude, computer skills, sector readiness, and interview preparation, supported by accessible infrastructure and trained professionals like sign-language interpreters and special educators.

Serving 14 types of disabilities, GROW PwD provides tailored curricula to meet diverse learning needs. In 2022, this initiative was honored with the National Award for Empowerment of Persons with Disabilities by the President of India.

We continue to build awareness and inclusion through sensitization sessions on hiring practices, inclusive language, accessibility, and empowering colleagues to voice their needs.

(reduced inequalities)

03/12/2025

We welcome the inclusion of Toripalimab on the Pharmaceutical Benefits Scheme (PBS) in Australia, a major milestone for patients living with nasopharyngeal cancer.

Nasopharyngeal cancer (NPC) develops in the nasopharynx, the upper part of the throat behind the nose. Around 200 Australians are diagnosed each year, with men over 40 most commonly affected, often in the prime of their lives.

Toripalimab is a next-generation PD-1 inhibitor, a type of immunotherapy that helps the immune system to detect and attack cancer cells. The medicine will now be available on the PBS for eligible patients.

It is indicated as:

-As a first-line treatment with chemotherapy for cancer that has returned or spread
-As a single therapy when the disease progresses during or after certain chemotherapy treatments

Click here to read more: https://shorturl.at/luz7m

(Good Health and well-being)

02/12/2025

Our in-house experience design team, Studio 5b, received three awards at the prestigious 15th CII Design Excellence Awards, held during the 25th CII Global Design Summit & Exposition 2025. The summit’s theme, “Design for People, Planet, Purpose and Profitability,” resonates deeply with our approach at Dr. Reddy’s to purposeful design.

Silver – Communication Design for Demystifying Pharma Animated Video Series

Bronze – Experience Design for Dr. Kallam Anji Reddy Memorial Audio Visual Experience

And, Top 50 Designs Made in India for Packaging Design

These recognitions celebrate how design can simplify complex ideas, create immersive experiences, and deliver meaningful impact.

01/12/2025

Today, we honour the progress made in the fight against HIV and reaffirm our commitment to a future free from it.

At Dr. Reddy’s, we are proud to partner with global health organizations—Gilead, CHAI, UNITAID, and WITS RHI—to advance access to Lenacapavir, a twice-yearly HIV prevention injection with potential to transform HIV care. It will be available in 120 low- and middle-income countries post regulatory approval at an affordable access price.

Together, we strive to expand access, challenge stigma, and ensure that innovation reaches those who need it most.

25/11/2025

We’re thrilled to share that the European Commission (EC) has granted marketing authorisation for AVT03, a biosimilar of Prolia® and Xgeva®—both denosumab medicines in different forms.

This approval, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in September, is valid across all EU Member States and the European Economic Area (EEA) countries including Iceland, Liechtenstein, and Norway.

Dr. Reddy’s will offer the biosimilar under the tradenames Acvybra® (60 mg/mL solution in a pre-filled syringe) and Xbonzy® (70 mg/mL solution in a vial). Denosumab works by blocking a protein that causes bone breakdown—helping reduce bone loss in conditions like osteoporosis and preventing bone damage in certain cancers.

With AVT03, our goal is to expand access to high-quality, affordable treatment options for millions affected by osteoporosis and cancer-related bone conditions—improving outcomes and reducing the burden of bone disease across Europe.

Click to read more:https://www.drreddys.com/cms/sites/default/files/2025-11/DRL-finalpressrelease-24thNov2025-Deno.pdf

24/11/2025

Satish Reddy, Chairman, Dr. Reddy’s Laboratories, joined industry leaders at the sixth Pre-Budget Consultation chaired by Hon’ble Union Finance Minister Smt. Nirmala Sitharaman in New Delhi.

He shared his perspective on the importance of risk-based innovation funding to strengthen India’s pharmaceutical ecosystem and accelerate breakthroughs that improve patient access and affordability.

At Dr. Reddy’s, we believe that partnerships between policymakers and industry are vital to building a future-ready healthcare system that serves millions.

Ministry of Finance, Government of India

14/11/2025

Diabetes is a major threat to global health, silently harming the heart, eyes, kidneys,
and more. Yet, over 40% of 589 million people living with diabetes don’t know they
have it. That’s every 9th person!

Watch out for early symptoms: extra thirst, frequent urination, fatigue after meals,
blurry vision and dark patches on the skin.
But sometimes, there are no signs at all, and that’s why screening matters.

Get yourself tested for diabetes if you run the risk.

To know your risk of having diabetes, click here: https://worlddiabetesday.org/type-2-
diabetes-risk-assessment/

(This online diabetes risk assessment is designed by International Diabetes Federation to predict an individual’s risk of developing type 2 diabetes within the next ten years. The test is based on the Finnish Diabetes Risk Score (FINDRISC) developed and designed by Adj. Prof Jaana Lindström and Prof. jaakko tuomilehto from the National Institute for Health and Welfare, Helsinki, Finland.)

Address

Dr. Reddy's Laboratories Limited (Corporate Office), Door No 8-2-337, Road No 3, Banjara Hills

500034

Website

https://www.drreddys.com/

Alerts

Be the first to know and let us send you an email when Dr. Reddy's Laboratories Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic?

Country:

City:

31/12/2025

22/12/2025

17/12/2025

12/12/2025

08/12/2025

03/12/2025

03/12/2025

02/12/2025

01/12/2025

25/11/2025

24/11/2025

14/11/2025

Address

Website

Alerts

Shortcuts

Share